Doctors Without Borders Calls on Wealthy Nations to Support WTO COVID-19 Vaccine Patent Waiver

International medical charity Doctors Without Borders (Medecins Sans Frontieres, or MSF) has urged wealthy countries to stop obstructing a patent waiver proposal that could significantly increase global production of COVID-19 vaccines. The call comes ahead of informal virtual talks scheduled by the World Trade Organization (WTO) on Thursday to discuss the waiver.

The waiver proposal seeks a temporary suspension of intellectual property (IP) rights related to COVID-19 vaccines and other coronavirus-related medical products for the duration of the pandemic. Proponents argue that this suspension would enable more manufacturers worldwide to produce vaccines without violating WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement.

Originally submitted in October 2020 by India and South Africa, the waiver has faced strong resistance from several high-income WTO members, many of which host major pharmaceutical companies. Notably, the United States and European Union countries have opposed the measure.

In a statement released on Wednesday, Dr Maria Guevara, MSF’s international medical secretary, appealed to these opponents to reconsider their stance. "In this COVID-19 pandemic, we are once again faced with issues of scarcity, which can be addressed through diversification of manufacturing and supply capacity and ensuring the temporary waiver of relevant intellectual property," she said.

Dr Guevara emphasized the moral imperative, stating, "We urge all countries in opposition to this, including the US and the EU, to stand on the right side of history and join hands with those in support. It is about saving lives at the end, not protecting systems."

Opponents of the waiver maintain that existing WTO rules already provide sufficient flexibility to support global vaccine supply. They also warn that suspending IP protections could undermine innovation by discouraging future investments in pharmaceutical research and development.

As the WTO prepares for further discussions—including a formal TRIPS Council meeting on April 30 and a General Council session in early May—supporters hope to advance from conceptual debate to concrete text-based negotiations.

Tahir Amin, co-founder and co-executive director of I-MAK, a global nonprofit advocating equitable access to medicines, remarked, "If we can get that by the next General Council meeting, it would be better than nothing, even if we are already six months late. It would show that we turned a corner."

However, Amin cautioned that opposing nations might continue to delay progress by encouraging bilateral agreements with pharmaceutical companies, thereby reducing pressure for a multilateral solution. "Pressure is building, but opposing countries will not want to get into text-based discussion—they don’t want to open that door, not even the window," he said.

The position of the United States remains pivotal. Last week, US Trade Representative Katherine Tai acknowledged the need for breakthroughs at the WTO. Observers noted that her comments marked a significant departure from the previous US administration’s rigid stance on intellectual property rights.

Tai also highlighted the importance of avoiding a repeat of the HIV/AIDS epidemic’s tragic consequences, where restrictive policies limited access to life-saving medicines in developing countries. "There should not be a repetition of the unnecessary deaths and suffering caused by policies and actions that constrained access to medicines," she said.

Yuanqiong Hu, legal adviser for MSF’s Access Campaign, described Tai’s statement as "a very positive sign," while noting uncertainty about how it would translate into concrete policy.

The urgency of the waiver debate is underscored by stark global vaccination disparities. According to World Health Organization estimates, one in four people in wealthy countries has received a COVID-19 vaccine dose, compared with only one in every 500 individuals in low-income nations.

Compounding challenges to global vaccine distribution, India recently imposed a temporary export suspension on AstraZeneca vaccines produced by the Serum Institute of India—the world’s largest vaccine manufacturer—to address a domestic surge in COVID-19 cases among its 1.4 billion population.

As the WTO deliberations continue, MSF and other health advocates maintain that a temporary waiver of intellectual property rights is essential to expanding vaccine manufacturing capacity and addressing global inequities in access to COVID-19 vaccines.